Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 2

The management of glaucoma and intraocular hypertension: current approaches and recent advances

Authors Robert J Noecker

Published 15 June 2006 Volume 2006:2(2) Pages 193—206

Robert J Noecker


University of Pittsburgh Medical Center, Eye and Ear Institute, Pittsburgh, PA, USA



Abstract: In the last decade, numerous novel ocular hypotensive agents have been introduced for the control of intraocular pressure (IOP). Clinicians now have more options than ever in the selection of medical therapy for the treatment of glaucoma and ocular hypertension. When selecting an ocular hypotensive medication for their patients, clinicians should consider not only the IOP-lowering efficacy of an agent, but also the ability of the drug to allow patients to achieve target levels of IOP that are low enough to stop the progression of glaucomatous damage. Other considerations should include how well the drug controls diurnal IOP, the likelihood of serious adverse events, the versatility of the medication for use as an adjunctive agent, as well as other potential attributes (ie, neuroprotection).



Keywords: glaucoma, ocular hypertension, intraocular pressure, target pressure

Download Article [PDF] 

Readers of this article also read:

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors

Sukasem C, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, Prommas S, Puangpetch A, Vathesatogkit P

Pharmacogenomics and Personalized Medicine 2013, 6:85-91

Published Date: 22 August 2013

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Ondansetron oral disintegrating tablets for the prevention of postoperative vomiting in children undergoing strabismus surgery

Deborah S Wagner, Virginia Gauger, Devi Chiravuri, Kristin Faust

Therapeutics and Clinical Risk Management 2007, 3:691-694

Published Date: 15 September 2007

Editorial ||FREE PAPER||

Garry Walsh

Therapeutics and Clinical Risk Management 2006, 2:127-128

Published Date: 15 June 2006